Receipt of opioid use disorder treatments prior to fatal overdoses and comparison to no treatment in Connecticut, 2016–17
Heimer R, Black A, Lin H, Grau L, Fiellin D, Howell B, Hawk K, D'Onofrio G, Becker W. Receipt of opioid use disorder treatments prior to fatal overdoses and comparison to no treatment in Connecticut, 2016–17. Drug And Alcohol Dependence 2023, 254: 111040. PMID: 38043226, PMCID: PMC10872282, DOI: 10.1016/j.drugalcdep.2023.111040.Peer-Reviewed Original ResearchConceptsNon-medication treatmentsRelative riskOpioid overdose deathsIncidence rateMOUD treatmentOverdose deathsOpioid use disorder treatmentResults Incidence ratesRetrospective cohort studyDifferent treatment modalitiesPopulation-level effortsUse disorder treatmentFatal opioid poisoningsCohort studyOpioid poisoningTreatment modalitiesConclusion ExposurePoisoning deathsFatal overdosesTreatment exposureDisorder treatmentDeathTreatmentMethadoneRiskAlcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy
Cartwright E, Pierret C, Minassian C, Esserman D, Tate J, Goetz M, Bhattacharya D, Fiellin D, Justice A, Re V, Rentsch C. Alcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy. JAMA Network Open 2023, 6: e2335715. PMID: 37751206, PMCID: PMC10523171, DOI: 10.1001/jamanetworkopen.2023.35715.Peer-Reviewed Original ResearchConceptsSustained virologic responseAlcohol use disorderHigh-risk consumptionHistory of AUDLow-risk consumptionDAA therapyAlcohol use categoriesAlcohol useVirologic responseCohort studyAntiviral therapyOdds ratioChronic hepatitis C virus (HCV) infectionAlcohol Use Disorders Identification Test-Consumption (AUDIT-C) questionnaireHepatitis C virus infectionVeterans AffairsActing antiviral (DAA) therapyDAA treatment initiationHCV elimination goalsUndetectable HCV RNAC virus infectionFibrosis-4 scoreRetrospective cohort studyMultivariable logistic regressionTenth Revision diagnosis